257 related articles for article (PubMed ID: 31026373)
1. Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes.
Miyoshi H; Kameda H; Yamashita K; Nakamura A; Kurihara Y
J Diabetes Investig; 2019 Nov; 10(6):1510-1517. PubMed ID: 31026373
[TBL] [Abstract][Full Text] [Related]
2. Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function.
Sada K; Hidaka S; Kashima J; Morita M; Sada K; Shibata H
J Diabetes Investig; 2022 Aug; 13(8):1330-1338. PubMed ID: 35322583
[TBL] [Abstract][Full Text] [Related]
3. Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes.
Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
J Am Heart Assoc; 2021 Jun; 10(11):e020237. PubMed ID: 34013739
[TBL] [Abstract][Full Text] [Related]
4. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models.
Kobayashi K; Toyoda M; Hatori N; Furuki T; Sakai H; Umezono T; Ito S; Suzuki D; Takeda H; Minagawa F; Degawa H; Yamamoto H; Machimura H; Chin K; Hishiki T; Takihata M; Aoyama K; Umezawa S; Minamisawa K; Aoyama T; Hamada Y; Suzuki Y; Hayashi M; Hatori Y; Sato K; Miyakawa M; Tamura K; Kanamori A
J Diabetes Investig; 2021 Jan; 12(1):74-81. PubMed ID: 32506833
[TBL] [Abstract][Full Text] [Related]
6. Initiation of sodium-glucose cotransporter-2 inhibitors at lower HbA1c threshold attenuates eGFR decline in type 2 diabetes patients with and without cardiorenal disease: A propensity-matched cohort study.
Cheung JTK; Yang A; Wu H; Lau ESH; Shi M; Kong APS; Ma RCW; Luk AOY; Chan JCN; Chow E
Diabetes Res Clin Pract; 2023 Jan; 195():110203. PubMed ID: 36493912
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice.
Hirai T; Kitada M; Monno I; Oda E; Hayashi Y; Shimada K; Takagaki Y; Ogura Y; Fujii M; Konishi K; Sakurai M; Nakagawa A; Koya D
J Diabetes Investig; 2021 Sep; 12(9):1577-1585. PubMed ID: 33417741
[TBL] [Abstract][Full Text] [Related]
8. The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Cardiovasc Diabetol; 2021 Aug; 20(1):167. PubMed ID: 34399757
[TBL] [Abstract][Full Text] [Related]
9. Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
Zhou T; Yao K; Xie Y; Lin Y; Wang J; Chen X
Curr Pharm Des; 2023; 29(21):1659-1670. PubMed ID: 37537933
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Kobayashi K; Toyoda M; Hatori N; Saito N; Kanaoka T; Sakai H; Furuki T; Umezono T; Ito S; Suzuki D; Takeda H; Minagawa F; Degawa H; Yamamoto H; Machimura H; Chin K; Hishiki T; Takihata M; Aoyama K; Umezawa S; Minamisawa K; Aoyama T; Hamada Y; Suzuki Y; Hayashi M; Hatori Y; Sato K; Miyakawa M; Tamura K; Kanamori A
Diabetes Technol Ther; 2021 Feb; 23(2):110-119. PubMed ID: 32721227
[No Abstract] [Full Text] [Related]
11. Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Classes of Glucose-Lowering Medications on Renal Outcome in Type 2 Diabetes.
Takeuchi M; Ogura M; Minoura T; Inagaki N; Kawakami K
Mayo Clin Proc; 2020 Feb; 95(2):265-273. PubMed ID: 32029085
[TBL] [Abstract][Full Text] [Related]
12. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
[TBL] [Abstract][Full Text] [Related]
13. Initial Acute Decline in Estimated Glomerular Filtration Rate After Sodium-Glucose Cotransporter-2 Inhibitor in Patients With Chronic Kidney Disease.
Sugiyama S; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T; Jinnouchi H
J Clin Med Res; 2020 Nov; 12(11):724-733. PubMed ID: 33224374
[TBL] [Abstract][Full Text] [Related]
14. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
[TBL] [Abstract][Full Text] [Related]
15. Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure.
Nakagaito M; Imamura T; Joho S; Ushijima R; Nakamura M; Kinugawa K
BMC Cardiovasc Disord; 2021 Jul; 21(1):347. PubMed ID: 34289813
[TBL] [Abstract][Full Text] [Related]
16. Initial eGFR Changes with SGLT2 Inhibitor in Patients With Type 2 Diabetes and Associations With the Risk of Abnormal Serum Potassium Level.
Kao YW; Chao TF; Chen SW; Cheng YW; Chan YH; Chu PH
J Am Heart Assoc; 2024 May; 13(9):e033236. PubMed ID: 38686902
[TBL] [Abstract][Full Text] [Related]
17. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Yan Y; Al-Aly Z
Diabetes Care; 2020 Nov; 43(11):2859-2869. PubMed ID: 32938746
[TBL] [Abstract][Full Text] [Related]
19. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience.
Tumminia A; Graziano M; Vinciguerra F; Lomonaco A; Frittita L
Prim Care Diabetes; 2021 Apr; 15(2):283-288. PubMed ID: 33129749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]